ACVR1B and lung adenocarcinoma: In models of lung adenocarcinoma, ALK4 expression was associated with reduced survival by promoting resistance to platinum chemotherapy; inhibition of ALK4 improved response to chemotherapy and reduced chemotherapy-induced nephrotoxicity (67).